The Investor
15 Sep 2026, 16:02
Gilead and PAHO Partner to Expand Twice-Yearly HIV Prevention Across Latin America
Gilead Sciences (NASDAQ: GILD) and the Pan American Health Organization announced a partnership aimed at expanding access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. The agreement will use PAHO’s Regional Revolving Funds to support country-led adoption and implementation of the long-acting PrEP treatment.
The agreement creates a new access pathway for 14 countries currently outside Gilead’s voluntary licensing agreements, including Brazil, Mexico, Argentina, Colombia and Chile. It complements existing generic-access programs and could significantly broaden the drug’s regional availability.
Lenacapavir requires only two doses per year and is already approved for HIV prevention in multiple countries. Gilead is also evaluating a once-yearly injectable version as part of its longer-term HIV prevention program.
The partnership represents another step in Gilead’s global commercialization and access strategy for lenacapavir. The company recently expanded its no-profit supply program with PEPFAR and the Global Fund by 50%, targeting access for as many as 3 million people through 2028.
Gilead Sciences (NASDAQ: GILD) and the Pan American Health Organization announced a partnership aimed at expanding access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. The agreement will use PAHO’s Regional Revolving Funds to support country-led adoption and implementation of the long-acting PrEP treatment.
The agreement creates a new access pathway for 14 countries currently outside Gilead’s voluntary licensing agreements, including Brazil, Mexico, Argentina, Colombia and Chile. It complements existing generic-access programs and could significantly broaden the drug’s regional availability.
Lenacapavir requires only two doses per year and is already approved for HIV prevention in multiple countries. Gilead is also evaluating a once-yearly injectable version as part of its longer-term HIV prevention program.
The partnership represents another step in Gilead’s global commercialization and access strategy for lenacapavir. The company recently expanded its no-profit supply program with PEPFAR and the Global Fund by 50%, targeting access for as many as 3 million people through 2028.
